Harvey J. Alter, Michael Houghton and Charles M. Rice   | Photo Credit: Nobelprize.org

The 2020 Nobel Prize in Physiology or Medicine was jointly awarded to Harvey J. Alter, Michael Houghton and Charles M. Rice for the discovery of Hepatitis C virus.

Hepatitis C is a blood-borne virus and causes Hepatitis C disease which affects the liver. According to WHO, “globally, an estimated 71 million people have chronic hepatitis C virus infection and a significant number develop cirrhosis or liver cancer."

In 2016, it was estimated that approximately 3,99,000 people died globally from hepatitis C.

Harvey J. Alter who was studying hepatitis in patients who had received blood transfusions, found many unexplained infections. Tests for Hepatitis A and Hepatitis B virus infection showed that they were not the cause. His team demonstrated that blood from these patients could transmit the disease to chimpanzees, and more studies showed that an unknown infectious agent was behind this. The mysterious new illness was termed “non-A, non-B” hepatitis.

Learn more about the 2020 #NobelPrize in Physiology or Medicine

Press release: https://t.co/eGxjMgrZTQ
Advanced information: https://t.co/60S9MjmLek pic.twitter.com/gN32y3HT3X

This new virus could not be isolated for several years using the traditional techniques for virus isolation. Michael Houghton and his team created a collection of DNA fragments from the blood of an infected chimpanzee and thoroughly searched it. They found a novel RNA virus belonging to the Flavivirus family and named it the Hepatitis C virus.

To understand if this new virus alone could cause hepatitis, Charles M. Rice used genetic engineering, generated an RNA variant of the virus and injected it into the liver of chimpanzees. The virus was detected in the blood and the chimpanzees exhibited changes similar to those seen in humans with the disease. This was the final proof that the virus alone was the cause behind the unexplained cases of transfusion-mediated hepatitis.

The discoveries by the three Nobel laureates have helped design sensitive blood tests that have eliminated the risk of transfusion-transmitted hepatitis. Their discovery also helped develop antiviral drugs directed at hepatitis C. This has now raised hopes of eradicating the virus from the world population.

You have reached your limit for free articles this month.

To get full access, please subscribe.

Already have an account ? Sign in

Start your 14 days free trial. Sign Up

Dear reader,

We have been keeping you up-to-date with information on the developments in India and the world that have a bearing on our health and wellbeing, our lives and livelihoods, during these difficult times. To enable wide dissemination of news that is in public interest, we have increased the number of articles that can be read free, and extended free trial periods. However, we have a request for those who can afford to subscribe: please do. As we fight disinformation and misinformation, and keep apace with the happenings, we need to commit greater resources to news gathering operations. We promise to deliver quality journalism that stays away from vested interest and political propaganda.

Dear subscriber,

Thank you!

Your support for our journalism is invaluable. It’s a support for truth and fairness in journalism. It has helped us keep apace with events and happenings.

The Hindu has always stood for journalism that is in the public interest. At this difficult time, it becomes even more important that we have access to information that has a bearing on our health and well-being, our lives, and livelihoods. As a subscriber, you are not only a beneficiary of our work but also its enabler.

We also reiterate here the promise that our team of reporters, copy editors, fact-checkers, designers, and photographers will deliver quality journalism that stays away from vested interest and political propaganda.

Suresh Nambath

Please enter a valid email address.

Subscribe to The Hindu now and get unlimited access.

Already have an account? Sign In

Start your 14 days free trial Sign Up

You can support quality journalism by turning off ad blocker or purchase a subscription for unlimited access to The Hindu.

Sign up for a 30 day free trial.